176 related articles for article (PubMed ID: 14746341)
21. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
22. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Cho WS; Jeong J; Choi M; Park SN; Han BS; Son WC
Arch Toxicol; 2011 Jan; 85(1):59-66. PubMed ID: 20358181
[TBL] [Abstract][Full Text] [Related]
23. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice.
Okamura M; Unami A; Moto M; Muguruma M; Ito T; Jin M; Oishi Y; Kashida Y; Mitsumori K
Cancer Lett; 2007 Jan; 245(1-2):321-30. PubMed ID: 16530936
[TBL] [Abstract][Full Text] [Related]
24. Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice.
Tomisawa M; Suemizu H; Ohnishi Y; Maruyama C; Urano K; Usui T; Yasuhara K; Tamaoki N; Mitsumori K
Toxicol Lett; 2003 Apr; 142(1-2):111-7. PubMed ID: 12765245
[TBL] [Abstract][Full Text] [Related]
25. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Nomura T
Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
[TBL] [Abstract][Full Text] [Related]
26. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modification by butylhydroxytoluene.
Umemura T; Kodama Y; Hioki K; Inoue T; Nomura T; Kurokawa Y
Cancer Lett; 1999 Oct; 145(1-2):101-6. PubMed ID: 10530776
[TBL] [Abstract][Full Text] [Related]
28. Lack of modifying effects of eugenol on development of lung proliferative lesions induced by urethane in transgenic mice carrying the human prototype c-Ha-ras gene.
Koujitani T; Yasuhara K; Tamura T; Onodera H; Takagi H; Takizawa T; Hirose M; Hayashi Y; Mitsumori K
J Toxicol Sci; 2001 Aug; 26(3):129-39. PubMed ID: 11552296
[TBL] [Abstract][Full Text] [Related]
29. Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis.
Park HJ; Oh JH; Park SM; Cho JW; Yum YN; Park SN; Yoon DY; Yoon S
Arch Toxicol; 2011 Dec; 85(12):1627-40. PubMed ID: 21607683
[TBL] [Abstract][Full Text] [Related]
30. The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens.
Umemura T; Kodama Y; Hioki K; Nomura T; Nishikawa A; Hirose M; Kurokawa Y
Jpn J Cancer Res; 2002 Aug; 93(8):861-6. PubMed ID: 12716462
[TBL] [Abstract][Full Text] [Related]
31. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
32. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
[TBL] [Abstract][Full Text] [Related]
33. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
Battershill JM; Fielder RJ
Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
[TBL] [Abstract][Full Text] [Related]
34. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
35. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
36. Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
Adachi T; Kuwamura Y; Fujiwara T; Tanimoto N; Nishimura T; Koguchi A; Kobayashi K; Sasaki Y; Yamaguchi C; Honda T; Kawashima K; Yuasa H; Yamamura T; Inui T
J Toxicol Sci; 2002 Aug; 27(3):147-63. PubMed ID: 12238139
[TBL] [Abstract][Full Text] [Related]
37. Tumor promoting effect of phenolphthalein on development of lung tumors induced by N-ethyl-N-nitrosourea in transgenic mice carrying human prototype c-Ha-ras gene.
Imaoka M; Kashida Y; Watanabe T; Ueda M; Onodera H; Hirose M; Mitsumori K
J Vet Med Sci; 2002 Jun; 64(6):489-93. PubMed ID: 12130832
[TBL] [Abstract][Full Text] [Related]
38. Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model.
Umemura T; Kodama Y; Nishikawa A; Hioki K; Nomura T; Kanki K; Kuroiwa Y; Ishii Y; Kurokawa Y; Hirose M
Cancer Lett; 2006 Jan; 231(2):314-8. PubMed ID: 16399233
[TBL] [Abstract][Full Text] [Related]
39. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
40. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
